Cotadutide

N/A

Report date: 2026/05/06 20:02:28
NME

Base Information

Drug NameCotadutide
Drug Alias NameMEDI-0382
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionGlucagon receptor agonistsGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptorGlucagon receptor
Therapy Area/IndicationsObesityDiabetes Mellitus, Type 2Diabetes Mellitus +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBulgariaCanada +[39] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesMedimmune Llc
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca PlcAstrazeneca AbAstrazeneca Investment (China) Co Ltd
Inactive CompaniesMedimmune LlcAstraZeneca global R & D (China) Co Ltd
Active IndicationsDiabetes Mellitus, Type 2Diabetes MellitusRenal Insufficiency, Chronic +[4] 
Inactive IndicationsObesityRenal InsufficiencyDiabetic Nephropathies +[4] 

Other Information

ATC CodeN/A
Related LinksN/A